nct_id: NCT05862285
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2023-05-17'
study_start_date: '2023-06-01'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Tiragolumab and Atezolizumab'
  - drug_name: 'Drug: Tiragolumab'
  - drug_name: 'Drug: Ipatasertib'
  - drug_name: 'Drug: Bevacizumab'
  - drug_name: 'Drug: Entrectinib'
  - drug_name: 'Drug: Atezolizumab'
  - drug_name: 'Drug: Inavolisib'
long_title: An Open-Label, Multicenter Extension Study in Patients Previously Enrolled
  in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study
last_updated: '2025-11-18'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE3
principal_investigator: NA
principal_investigator_institution: Hoffmann-La Roche
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 60
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* Eligible for continuing Roche IMP-based therapy at the time of roll-over from
  the parent study, as per the parent study protocol OR'
- '* Eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored
  study as per the parent study protocol, with no access to commercially available
  comparator agent'
- '* First dose of study treatment in this extension study will be received within
  7 days of the treatment interruption window allowed by the parent study'
- '* Continue to benefit from the Roche IMP-based therapy or comparator at the time
  of roll-over from the parent study as assessed by the investigator'
- '* Ability to comply with the extension study protocol, per Investigator''s judgement'
- 'Exclude - Exclusion Criteria:'
- Exclude - * Meet any of the study treatment discontinuation criteria specified in
  the parent study at the time of enrollment in this extension study
- Exclude - * Study treatment or comparator agent is commercially marketed in the
  participant's country for the participant-specific disease and is accessible to
  the participant
- Exclude - * Treatment with any anti-cancer treatment (other than treatment permitted
  in the parent study) during the time between last treatment in the parent study
  and the first dose of study treatment in this extension study
- Exclude - * Permanent discontinuation of all study treatment(s) or comparator agent(s)
  for any reason during the parent study or during the time between last treatment
  in the parent study and the first dose of study treatment in this extension study
  (if applicable)
- "Exclude - * Ongoing SAE(s) that has not resolved to baseline level or Grade \u2264\
  1 from the parent study or during the time between the last treatment in the parent\
  \ study and the first dose of study treatment in this extension study"
- Exclude - * Concurrent participation in any therapeutic clinical trial (other than
  the parent study)
short_title: A Rollover Study for Participants Previously Enrolled in a Genentech
  and/or F. Hoffman-La Roche Sponsored Study
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Hoffmann-La Roche
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The purpose of this extension study is to provide continued treatment with
  Roche investigational medicinal product (IMP\[s\]) monotherapy or Roche IMP(s) combined
  with other agent(s) or comparator agent(s) for eligible participants with cancer
  who are still on study treatment at the time of roll-over from the parent study
  and who do not have access to the study treatment locally.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Roche IMP(s) Monotherapy
      arm_internal_id: 0
      arm_description: Participants will continue to receive Roche IMP(s) monotherapy
        as per parent protocol, until disease progression, loss of clinical benefit
        as judged by the investigator, death, withdrawal of study consent, unacceptable
        toxicity, pregnancy, participants non-compliance, if local access becomes
        available or study termination by the Sponsor, whichever occurs first.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Ipatasertib'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Atezolizumab'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Bevacizumab'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: Entrectinib'
        level_internal_id: 3
        level_suspended: N
      - level_code: '4'
        level_description: 'Drug: Inavolisib'
        level_internal_id: 4
        level_suspended: N
    - arm_code: Roche Combined Agents
      arm_internal_id: 1
      arm_description: Participants will continue to receive Roche IMP(s) in combination
        with other agent(s) as per parent protocol, until disease progression, loss
        of clinical benefit as judged by the investigator, death, withdrawal of study
        consent, unacceptable toxicity, pregnancy, participants non-compliance, if
        local access becomes available or study termination by the Sponsor, whichever
        occurs first.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Tiragolumab'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Atezolizumab'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Tiragolumab and Atezolizumab'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: Bevacizumab'
        level_internal_id: 3
        level_suspended: N
      - level_code: '4'
        level_description: 'Drug: Inavolisib'
        level_internal_id: 4
        level_suspended: N
    match:
    - and:
      - or:
        - clinical:
            oncotree_primary_diagnosis: _SOLID_
        - clinical:
            oncotree_primary_diagnosis: _LIQUID_
      - clinical:
          age_numerical: '>=18'
